Close Menu

NEW YORK – Curetis and OpGen announced today that the two companies have entered into a definitive agreement to combine businesses.

The transaction will be structured as an acquisition by OpGen of Curetis GmbH, a subsidiary of Curetis that owns all of the Curetis Group business. Upon closing of the transaction, which is expected in early 2020, Curetis GMbH will become a wholly owned subsidiary of OpGen.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.